The Journal of Practical Medicine ›› 2024, Vol. 40 ›› Issue (20): 2900-2904.doi: 10.3969/j.issn.1006-5725.2024.20.013
• Clinical Research • Previous Articles Next Articles
Xi CHEN1,Huan WANG1,Xiaolong LI1,Li SHEN1,Hongtao LIU1,Biwei WANG1,Hongwei ZHAO2
Received:
2024-04-01
Online:
2024-10-25
Published:
2024-11-05
CLC Number:
Xi CHEN,Huan WANG,Xiaolong LI,Li SHEN,Hongtao LIU,Biwei WANG,Hongwei ZHAO. The predictive value of NK cells combined with Treg cells for TKI discontinuation in patients with chronic myeloid leukemia[J]. The Journal of Practical Medicine, 2024, 40(20): 2900-2904.
Tab.1
Comparison of basic clinical features between the"
项目 | 停药组 (n = 100) | 未停药组 (n = 100) | χ2/t值 | P值 |
---|---|---|---|---|
年龄[M(P25,P75)]/岁 | 42(36,52) | 44(31,56) | 1.452 | 0.162 |
BMI(x ± s)/(kg/m2) | 25.32 ± 5.12 | 22.86 ± 6.23 | 1.936 | 0.093 |
性别 | 1.263 | 0.156 | ||
男 | 41 | 52 | ||
女 | 59 | 48 | ||
Sokal评分 | 1.059 | 0.447 | ||
低危 | 44 | 40 | ||
中危 | 23 | 25 | ||
高危 | 11 | 18 | ||
未知 | 22 | 17 | ||
应用干扰素 | 22.102 | 0.016 | ||
是 | 61 | 43 | ||
否 | 39 | 57 | ||
NK细胞(x ± s)/(个/L) | 18.45 ± 3.16 | 11.27 ± 3.83 | 14.358 | 0.024 |
Treg细胞(x ± s)/(个/L) | 14.21 ± 2.69 | 6.15 ± 2.18 | 31.264 | 0.005 |
Tab.2
Comparison of basic clinical features between the"
项目 | 复发组 (n = 41) | 未复发组 (n = 59) | χ2/t值 | P值 |
---|---|---|---|---|
年龄[M(P25,P75)]/岁 | 43(38,54) | 42(32,58) | 1.232 | 0.265 |
BMI(x ± s)/(kg/m2) | 24.12 ± 4.97 | 25.91 ± 5.45 | 1.369 | 0.152 |
性别 | 5.716 | 0.083 | ||
男 | 21 | 20 | ||
女 | 20 | 39 | ||
Sokal评分 | 0.815 | 0.527 | ||
低危 | 16 | 28 | ||
中危 | 8 | 15 | ||
高危 | 6 | 5 | ||
未知 | 11 | 11 | ||
应用干扰素 | 22.631 | 0.012 | ||
是 | 19 | 42 | ||
否 | 22 | 17 | ||
停药时年龄[M(P25,P75)]/岁 | 49(41,58) | 47(38,61) | 2.847 | 0.073 |
TKI治疗时间[M(P25,P75)]/月 | 61(42,72) | 78(53,90) | 9.195 | 0.022 |
DMR持续时间[M(P25,P75)]/月 | 42(36,68) | 56(48,82) | 24.356 | 0.009 |
NK细胞(x ± s)/(个/L) | 14.23 ± 2.68 | 20.22 ± 3.16 | 29.534 | 0.008 |
Treg细胞(x ± s)/(个/L) | 10.18 ± 3.01 | 19.35 ± 3.88 | 42.106 | 0.001 |
1 | 刘孝荣, 何悦, 陈妍, 等. 利用慢病毒载体构建过表达人TCRP1基因的慢性髓系白血病K562细胞系及其生物学功能检[J].实用医学杂志, 2023,39(19): 2456-2460. |
2 |
HADDAD F G, KANTARJIAN H. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors[J]. J Natl Compr Canc Netw,2024,22(1):e237116. doi:10.6004/jnccn.2023.7116
doi: 10.6004/jnccn.2023.7116 |
3 |
BOWER H, BJORKHOLM M, DICKMAN P W,et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population[J]. J Clin Oncol,2016,34(24): 2851-2857. doi:10.1200/jco.2015.66.2866
doi: 10.1200/jco.2015.66.2866 |
4 |
STEEGMANN J L, BACCARANI M, BRECCIA M,et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia[J]. Leukemia,2016,30(8): 1648-1671. doi:10.1038/leu.2016.104
doi: 10.1038/leu.2016.104 |
5 |
丁宇轩,郭沥泞,沈佳怡,等. 放疗联合PD-1抑制剂及酪氨酸激酶抑制剂治疗MSS型结直肠癌肝转移疗效及安全性[J]. 实用医学杂志,2024,40(9):1293-1297. doi:10.3969/j.issn.1006-5725.2024.09.019
doi: 10.3969/j.issn.1006-5725.2024.09.019 |
6 |
HOCHHAUS A, BACCARANI M, SILVER R T, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia[J]. Leukemia,2020,34(4): 966-984. doi:10.1038/s41375-020-0776-2
doi: 10.1038/s41375-020-0776-2 |
7 |
CHEN K K, DU T F, XIONG P S, et al. Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis[J]. Front Oncol,2019, 9(3): 372. doi:10.3389/fonc.2019.00372
doi: 10.3389/fonc.2019.00372 |
8 |
INZOLI E, AROLDI A, PIAZZA R, et al. Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success[J]. Am J Hematol,2022, 97(8): 1075-1085. doi:10.1002/ajh.26556
doi: 10.1002/ajh.26556 |
9 |
GAMBACORTI-PASSERINI C. Part I: Milestones in personalised medicine-imatinib[J]. Lancet Oncol,2008, 9(6): 600. doi:10.1016/s1470-2045(08)70152-9
doi: 10.1016/s1470-2045(08)70152-9 |
10 |
SAVAS E M, YILMAZ S, BASER DIKYAR A A,et al. Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study[J]. Turk J Haematol,2023,40(4): 236-241. doi:10.4274/tjh.galenos.2023.2023.0194
doi: 10.4274/tjh.galenos.2023.2023.0194 |
11 | DEININGER M W, SHAH N P, ALTMAN J K,et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw,2020, 18(10): 1385-1415. |
12 |
SCHEICH F, DUYSTER J, PESCHEL C, et al. The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens[J]. Blood,2007, 110(7): 2556-2560. doi:10.1182/blood-2007-01-071001
doi: 10.1182/blood-2007-01-071001 |
13 |
HSIEH Y C, KIRSCHNER K, COPLAND M. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape[J]. Leukemia,2021,35(5): 1229-1242. doi:10.1038/s41375-021-01238-w
doi: 10.1038/s41375-021-01238-w |
14 |
HUGHES A, YONG A S M. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission[J]. Front Immunol,2017,8(1): 469. doi:10.3389/fimmu.2017.00469
doi: 10.3389/fimmu.2017.00469 |
15 |
贾王强,倪红谚,袁龙. FGL-1作为LAG-3主要的免疫抑制配体在恶性肿瘤中的研究进展[J]. 实用医学杂志,2021,37(4):547-551. doi:10.3969/j.issn.1006-5725.2021.04.026
doi: 10.3969/j.issn.1006-5725.2021.04.026 |
16 | 姚磊,颜巍,闫宇博,等. 驱动基因阴性非小细胞肺癌患者新辅助免疫治疗手术后预后的影响因素[J]. 实用医学杂志,2021,37(21):2748-2751,2756. |
17 |
BACHY E, BERNAUD J, ROY P, et al. Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate[J]. Br J Haematol,2011,153(1): 139-143. doi:10.1111/j.1365-2141.2010.08453.x
doi: 10.1111/j.1365-2141.2010.08453.x |
18 |
HUGHES A, CLARSON J, TANG C,et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors[J]. Blood,2017,129(9): 1166-1176. doi:10.1182/blood-2016-10-745992
doi: 10.1182/blood-2016-10-745992 |
19 |
BRUCK O, BLOM S, DUFVA O,et al. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML[J]. Leukemia,2018, 32(7): 1643-1656. doi:10.1038/s41375-018-0175-0
doi: 10.1038/s41375-018-0175-0 |
20 |
KIM J, PARK J, MOON Y,et al. Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis[J]. Int J Hematol,2019, 110(6): 683-689. doi:10.1007/s12185-019-02744-5
doi: 10.1007/s12185-019-02744-5 |
21 |
ILANDER M, OLSSON-STROMBERG U, SCHLUMS H,et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia[J]. Leukemia,2017,31(5): 1108-1116. doi:10.1038/leu.2016.360
doi: 10.1038/leu.2016.360 |
22 |
REA D, HENRY G, KHAZNADAR Z,et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study[J]. Haematologica,2017,102(8): 1368-1377. doi:10.3324/haematol.2017.165001
doi: 10.3324/haematol.2017.165001 |
23 |
OKADA M, IMAGAWA J, TANAKA H,et al. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment[J]. Clin Lymphoma Myeloma Leuk,2018, 18(5): 353-360. e351. doi:10.1016/j.clml.2018.03.004
doi: 10.1016/j.clml.2018.03.004 |
24 |
IRANI Y D, HUGHES A, CLARSON J,et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells[J]. Br J Haematol,2020,191(3): 433-441. doi:10.1111/bjh.16718
doi: 10.1111/bjh.16718 |
25 |
VIGON L, LUNA A, GALAN M,et al. Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission[J]. J Clin Med,2020,10(1): 42-51. doi:10.1182/blood-2019-130017
doi: 10.1182/blood-2019-130017 |
26 |
CAYSSIALS E, JACOMET F, PICCIRILLI N,et al. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells[J]. Br J Haematol,2019, 186(1): 54-59. doi:10.1111/bjh.15858
doi: 10.1111/bjh.15858 |
27 |
MUSTJOKI S, AUVINEN K, KREUTZMAN A,et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy[J]. Leukemia,2013,27(4): 914-924. doi:10.1038/leu.2012.348
doi: 10.1038/leu.2012.348 |
28 |
HUGHES T P, SAGLIO G, KANTARJIAN H M,et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib[J]. Blood,2014, 123(9): 1353-1360. doi:10.1182/blood-2013-06-510396
doi: 10.1182/blood-2013-06-510396 |
29 |
CORTES J E, SAGLIO G, KANTARJIAN H M,et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial[J]. J Clin Oncol,2016, 34(20): 2333-2340. doi:10.1200/jco.2015.64.8899
doi: 10.1200/jco.2015.64.8899 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||